Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP trimmed its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 17.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 347,532 shares of the company's stock after selling 72,056 shares during the quarter. Two Sigma Investments LP owned about 0.58% of Twist Bioscience worth $16,150,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in TWST. Teza Capital Management LLC acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $204,000. Sherbrooke Park Advisers LLC acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $238,000. ProShare Advisors LLC lifted its holdings in shares of Twist Bioscience by 30.5% in the 4th quarter. ProShare Advisors LLC now owns 19,226 shares of the company's stock valued at $893,000 after buying an additional 4,488 shares during the period. Nuveen Asset Management LLC lifted its holdings in shares of Twist Bioscience by 43.8% in the 4th quarter. Nuveen Asset Management LLC now owns 292,645 shares of the company's stock valued at $13,599,000 after buying an additional 89,170 shares during the period. Finally, Lazard Asset Management LLC lifted its holdings in shares of Twist Bioscience by 39.0% in the 4th quarter. Lazard Asset Management LLC now owns 27,881 shares of the company's stock valued at $1,295,000 after buying an additional 7,827 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TWST. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. reduced their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Guggenheim reissued a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. Barclays reduced their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Finally, Robert W. Baird dropped their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $50.40.

Insiders Place Their Bets

In other news, COO Patrick John Finn sold 1,877 shares of the firm's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total transaction of $55,840.75. Following the sale, the chief operating officer now owns 240,783 shares in the company, valued at $7,163,294.25. This trade represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Emily M. Leproust sold 2,402 shares of the company's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $98,265.82. Following the completion of the transaction, the chief executive officer now owns 662,692 shares of the company's stock, valued at $27,110,729.72. The trade was a 0.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,011 shares of company stock valued at $951,499. Corporate insiders own 3.01% of the company's stock.

Twist Bioscience Price Performance

NASDAQ TWST traded down $0.50 during mid-day trading on Wednesday, hitting $28.91. The stock had a trading volume of 272,849 shares, compared to its average volume of 976,000. Twist Bioscience Co. has a 52-week low of $27.12 and a 52-week high of $60.90. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -8.54 and a beta of 2.54. The company has a 50 day simple moving average of $36.19 and a 200 day simple moving average of $42.60. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The company had revenue of $92.79 million for the quarter, compared to analysts' expectations of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Equities analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.